Floatz logo

FDOPA

Recurrent Childhood Oligoastrocytoma

Erik MittraSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Recurrent Childhood Oligoastrocytoma cohort.

Asset / SponsorPhaseRating
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 1/2BB
CHLOROTOXIN
TransMolecular
Phase 2CCC
ETOPOSIDE
Washington University School of Medicine
Phase 2CCC
Inno-206
Washington University School of Medicine
Phase 2CCC
Interferon Beta
Biogen
Phase 1CC

View all 12 →

Same molecule, other indications

FDOPA is also rated in:

congenital isolated hyperinsulinismDormant
BB
Indicative ·
66 / 100
View asset →
brain gliomaDormant
B
Indicative ·
63 / 100
View asset →
Lewy body dementiaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →